Nov 17, 2021 Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
Oct 25, 2021 Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
Apr 13, 2021 Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
Dec 18, 2020 Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
Dec 18, 2020 Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
